A+C in Metastatic Lung Adenocarcinoma Cancer

Inclusion Criteria: * Histologically confirmed diagnosis of lung adenocarcinoma cancer * Availability of tumor tissue for ROS1, ALK, MET analyses * EGFR was wild type, positive for ROS1 translocation or ALK translocation or MET amplification * At least one radiological measurable disease according to RECIST criteria (Response Evaluation Criteria in Solid Tumors ) * Patient didn't received any therapy for lung cancer before except surgery or radiotherapy, or the adjuvant chemotherapy had stopped for more than 12 months * Performance status 0-2 (ECOG) * Patient compliance to trial procedures * age ≥ 18 years * Written informed consent * Adequate BM function (ANC ≥ 1.5x109/L, Platelets ≥ 100x109/L, HgB \> 9g/dl) * Adequate liver function (bilirubin \<G2, transaminases no more than 3xULN/\<5xULN in present of liver metastases). * Normal level of alkaline phosphatase and creatinine. * If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of approved contraceptive method \[intrauterine contraceptive device (IUD), birth control pills, or barrier device\] during and for ninety(90) days after end of treatment. Exclusion Criteria: * Patients with EGFR mutation * No tumor tissue available or patient negative for ALK translocation or ROS1 translocation or MET amplification * Absence of any measurable lesion * Prior therapy with bevacizumab or ipilimumab * Symptomatic brain metastases * Previous radiotherapy on the target lesion(s…